Key Drivers
- Margin expansion
- Cash generation
- Elevated debt
AIAI Summary
Haemonetics has transitioned from a pure growth story to a value-recovery, cash-generation play where the equity upside now hinges on execution—sustaining ~60% gross margins and FCF >$200M to deleverage and validate buybacks—so investors should watch sequential consumables/revenue stabilization and FCF consistency as the primary catalysts, while failure to arrest organic declines or reduce leverage (and potential goodwill impairment) would sharply compress equity value.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin expansion
- •Cash generation
- •Elevated debt
Haemonetics shows improving margins, stronger liquidity and steady cash generation but remains exposed to elevated leverage and large intangibles that heighten impairment and financial risk.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Trading below mean
- •Lower highs/lows
HAE is in a short-term downtrend from last month, trading ~5% below its last-month mean and sitting near support at $58.60 with resistance around $64–$65, so watch for a sustained move above ~$61.8 to signal stabilization or a break below $58.6 to confirm continuation.
~4.2% decline from $61.19 to $58.58 over last month indicating short-term weakness
Sentiment & News
Key News Insights:
- •FDA 510(k) clearance
- •Institutional buying interest
- •Leverage and competition
Haemonetics' FDA 510(k) clearance for NexSys PCS and early adoption plus institutional buying bolster a growth narrative, but analyst praise is largely stylistic and near-term upside is tempered by a leveraged balance sheet and stiff competition.
The regulatory win and adoption should drive near-term revenue momentum and investor interest, but leverage and competitive risks may limit sustained upside until execution and balance-sheet improvement are demonstrated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings